ProCE Banner Activity

Phase I Study of Ivosidenib, an Investigational IDH Inhibitor, in Relapsed/Refractory IDH1-Mutated Acute Myeloid Leukemia

Slideset Download
Conference Coverage
Ivosidenib produced durable responses in heavily pretreated patients with relapsed/refractory IDH1-mutated AML.

Released: June 04, 2018

Expiration: June 03, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen